Published in Gut on February 01, 1994
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut (2005) 3.31
Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut (2011) 2.87
Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI). Dig Dis Sci (2007) 1.96
Ulcerative colitis and Crohn's disease. BMJ (1994) 1.43
Risk of postoperative recurrence and postoperative management of Crohn's disease. World J Gastroenterol (2011) 1.12
Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut (1998) 1.11
Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am (2014) 1.05
Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn's disease. J Clin Gastroenterol (2014) 0.99
Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol (2011) 0.99
Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls. Dig Dis Sci (1997) 0.98
Mucosal immunology research design should address not just cytokines and cells, but also clinical data and controls. Clin Exp Immunol (1994) 0.94
Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol (2010) 0.93
Measuring disease activity in Crohn's disease: what is currently available to the clinician. Clin Exp Gastroenterol (2014) 0.92
C-reactive protein and disease activity in children with Crohn's disease. Dig Dis Sci (2010) 0.91
Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel disease. Clin Transl Gastroenterol (2012) 0.90
Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol (2010) 0.88
Rectal administration of d-alpha tocopherol for active ulcerative colitis: a preliminary report. World J Gastroenterol (2008) 0.87
C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol (2008) 0.87
Influence of disease site and activity on peripheral neutrophil function in inflammatory bowel disease. Dig Dis Sci (2000) 0.86
Predictive value of time-intensity curves obtained with contrast-enhanced ultrasonography (CEUS) in the follow-up of 30 patients with Crohn's disease. J Ultrasound (2009) 0.85
Evaluating bowel wall vascularity in Crohn's disease: a comparison of dynamic MRI and wideband harmonic imaging contrast-enhanced low MI ultrasound. Eur Radiol (2006) 0.85
Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol (2007) 0.85
B lymphocyte intestinal homing in inflammatory bowel disease. BMC Immunol (2011) 0.84
Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease. World J Gastroenterol (2012) 0.84
Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders. World J Gastroenterol (2006) 0.83
Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. Gut (1996) 0.82
The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol (2014) 0.81
Evaluation of new therapies for inflammatory bowel disease. Br J Clin Pharmacol (2003) 0.81
Laboratory markers in ulcerative colitis: Current insights and future advances. World J Gastrointest Pathophysiol (2015) 0.81
Can fecal calprotectin better stratify Crohn's disease activity index? Ann Gastroenterol (2015) 0.81
Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. Ann Gastroenterol (2015) 0.80
Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin. Inflamm Bowel Dis (2015) 0.80
Disease monitoring in inflammatory bowel disease. World J Gastroenterol (2015) 0.80
Calprotectin as a diagnostic tool for inflammatory bowel diseases. Biomed Rep (2016) 0.79
Are we giving biologics too much time? When should we stop treatment? World J Gastroenterol (2008) 0.79
Inflammatory Bowel Disease Patients' Willingness to Accept Medication Risk to Avoid Future Disease Relapse. Am J Gastroenterol (2015) 0.79
Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin? Intest Res (2016) 0.78
Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care. World J Gastroenterol (2013) 0.77
Circulating cytokines reflect mucosal inflammatory status in patients with Crohn's disease. Dig Dis Sci (2009) 0.77
Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol (2015) 0.77
Guided treatment improves outcome of patients with enterocutaneous fistulas. World J Surg (2012) 0.77
Medical management of Crohn's disease. Clin Colon Rectal Surg (2007) 0.76
Radiological Response Is Associated With Better Long-Term Outcomes and Is a Potential Treatment Target in Patients With Small Bowel Crohn's Disease. Am J Gastroenterol (2016) 0.76
Effect of tumor necrosis factor-α antagonists on oxidative stress in patients with Crohn's disease. World J Gastroenterol (2015) 0.75
Analysis of the clinical indications for opiate use in inflammatory bowel disease. Intest Res (2017) 0.75
Endoluminal ultrasound biomicroscopy as a reliable tool for in vivo assessment of colonic inflammation in rats. Int J Colorectal Dis (2013) 0.75
Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers. BMC Med Imaging (2016) 0.75
Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn's Disease: Results from the CONNECT Study. Gut Liver (2016) 0.75
Serum concentrations of insulin-like growth factor-binding protein 5 in Crohn's disease. World J Gastroenterol (2013) 0.75
MR enterography: how to deliver added value. Pediatr Radiol (2016) 0.75
Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease. Intest Res (2017) 0.75
Predictability of the postoperative course of Crohn's disease. Gastroenterology (1990) 5.30
Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology (1979) 3.94
An index of inflammatory activity in patients with Crohn's disease. Gut (1980) 2.62
Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology (1990) 2.58
Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest (1982) 2.48
Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease. Gastroenterology (1983) 2.37
Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut (1986) 2.17
Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut (1981) 2.00
Faecal alpha-1-antitrypsin and excretion of 111indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases. Gut (1987) 1.54
Fecal alpha 1-antitrypsin measurement: an indicator of Crohn's disease activity. Gastroenterology (1985) 1.53
T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells. Gastroenterology (1990) 1.42
Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology (1992) 1.39
[Proposal of a system of criteria for the diagnosis of cryptogenetic inflammatory enterocolitis (Crohn's disease and hemorrhagic rectocolitis). A cooperative study by the Cryptogenic Enterocolitis Study Group]. Gastroenterol Clin Biol (1978) 1.30
Reproducibility of colonoscopic findings in Crohn's disease: a prospective multicenter study of interobserver variation. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Dig Dis Sci (1987) 1.19
Alpha 1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn's disease. Gut (1983) 1.16
Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol (1986) 1.08
Relationship between clinical and laboratory parameters and length of lesion in Crohn's disease of small bowel. Dig Dis Sci (1984) 0.97
[Evaluation of ulcerative colitis and Crohn's disease activity by measurement of alpha-1-antitrypsin intestinal clearance (author's transl)]. Gastroenterol Clin Biol (1981) 0.92
Antiinflammatory treatment and intestinal alpha 1-antitrypsin clearance in active Crohn's disease. Dig Dis Sci (1985) 0.86
Depth of ulceration in acute colitis: correlation with outcome and clinical and radiologic features. Gastroenterology (1980) 0.85
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med (1997) 4.94
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut (2001) 4.23
Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst (1996) 4.22
Occurrence of a new microsporidan: Enterocytozoon bieneusi n.g., n. sp., in the enterocytes of a human patient with AIDS. J Protozool (1985) 4.11
Emergency liver transplantation for acute liver failure. Evaluation of London and Clichy criteria. J Hepatol (1993) 3.24
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet (1996) 3.15
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology (2000) 2.78
Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Aliment Pharmacol Ther (2012) 2.74
Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology (1990) 2.58
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer (2001) 2.58
Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet (1996) 2.41
Genetic analyses of chromosome 12 loci in Crohn's disease. Gut (2000) 2.30
Gut-hormone profile in coeliac disease. Lancet (1978) 2.25
Diagnostic value of endoscopic capsule in patients with obscure digestive bleeding: blinded comparison with video push-enteroscopy. Endoscopy (2003) 2.20
Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol (1998) 2.20
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol (1998) 2.15
Anticipation in Crohn's disease may be influenced by gender and ethnicity of the transmitting parent. Am J Gastroenterol (1998) 2.14
Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gastroenterology (1994) 2.07
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer (1997) 2.04
Expansion by folinic acid of the peripheral blood progenitor pool after chemotherapy: its use in autografting in acute leukaemia. Br J Haematol (1990) 2.02
Influence of chronic lactulose ingestion on the colonic metabolism of lactulose in man (an in vivo study). J Clin Invest (1985) 2.00
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther (2004) 1.87
A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol (1997) 1.85
Intestinal lymphangiectasia: lack of efficacy of antiplasmin therapy? Gastroenterology (1991) 1.76
Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) Gastroenterology (1993) 1.71
Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology (1998) 1.71
Clinical characteristics of Crohn's disease in 72 families. Gastroenterology (1996) 1.70
Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol (2000) 1.69
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride. Dig Dis Sci (1989) 1.63
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther (2004) 1.62
Bone metastasis revealing hepatocellular carcinoma: a report of three cases with a long clinical course. Am J Gastroenterol (1995) 1.61
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol (2002) 1.61
Measurement of gastric emptying in dyspeptic patients: effect of a new gastrokinetic agent (cisapride). Gut (1985) 1.60
Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab (2001) 1.58
Role of adhesion molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells. Blood (1998) 1.56
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer (1997) 1.52
What role can endoscopy play in the management of biliary complications after laparoscopic cholecystectomy? Endoscopy (1997) 1.52
Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia (1997) 1.50
The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun (2007) 1.50
Low rectal volumes in patients suffering from fecal incontinence: what does it mean? Aliment Pharmacol Ther (2005) 1.49
Anal lesions: any significant prognosis in Crohn's disease? Eur J Gastroenterol Hepatol (1997) 1.49
Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study. Eur J Gastroenterol Hepatol (2001) 1.46
[Cystic tumors and endocrine tumor of the pancreas. An unusual association]. Gastroenterol Clin Biol (1993) 1.45
Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology (1997) 1.44
[Treatment of Crohn's disease with azathioprine or 6-mercaptopurine. Retrospective study of 126 cases]. Gastroenterol Clin Biol (1990) 1.44
Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol (2002) 1.44
Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum (2001) 1.44
Seasonal variations in egg passage of Fasciola hepatica in dairy cows in Quebec. Vet Parasitol (1986) 1.44
Use of scanning electron microscopy to investigate dental calculus in dogs. Vet Rec (1990) 1.43
Histological discrimination of idiopathic inflammatory bowel disease from other types of colitis. J Clin Pathol (1995) 1.43
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol (1998) 1.42
Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin. Lancet (1978) 1.41
[Infliximab therapy for Crohn's disease anoperineal lesions]. Gastroenterol Clin Biol (2001) 1.40
Abdominal radiotherapy is a cause for chronic pancreatitis. Gastroenterology (1993) 1.40
Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology (1992) 1.39
Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment. Gut (1999) 1.39
Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood (1995) 1.39
Intestinal clearance of alpha 1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy. Gastroenterology (1981) 1.39
A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol (2002) 1.38
Mesalazine as a maintenance treatment in Crohn's disease: is it the long awaited solution? Gut (1997) 1.38
The method of intraluminal perfusion of the human small intestine. I. Principle and technique. Digestion (1973) 1.37
[Black esophagus. Three new cases]. Gastroenterol Clin Biol (1993) 1.37
[Cerebrovascular accidents after endoscopic obturation of esophageal varices with isobutyl-2-cyanoacrylate in 2 patients]. Gastroenterol Clin Biol (1987) 1.33
Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci (1994) 1.31
Intestinal microsporidiosis in human immunodeficiency virus-infected patients with chronic unexplained diarrhea: prevalence and clinical and biologic features. J Infect Dis (1993) 1.30
[Proposal of a system of criteria for the diagnosis of cryptogenetic inflammatory enterocolitis (Crohn's disease and hemorrhagic rectocolitis). A cooperative study by the Cryptogenic Enterocolitis Study Group]. Gastroenterol Clin Biol (1978) 1.30
Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol (2000) 1.30
Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol (1996) 1.27
A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol (1999) 1.27
Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab (1999) 1.25
Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer (1992) 1.24
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev (2000) 1.24
Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat (2010) 1.23
Distinction between coeliac disease and refractory sprue: a simple immunohistochemical method. Histopathology (2000) 1.22
Clinical impact of capsule endoscopy compared to push enteroscopy: 1-year follow-up study. Endoscopy (2005) 1.22